**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76061

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Prognostic role of multiple abnormal genes in non-small-cell lung cancer**

Yan LD *et al*. Genes in non-small-cell lung cancer

Lu-Da Yan, Liu Yang, Na Li, Meng Wang, Yan-Hua Zhang, Wen Zhou, Zhi-Qiong Yu, Xiao-Chun Peng, Jun Cai

**Lu-Da Yan, Liu Yang, Na Li, Meng Wang, Yan-Hua Zhang, Wen Zhou, Zhi-Qiong Yu, Jun Cai,** Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou 434023, Hubei Province, China

**Xiao-Chun Peng,** Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou 434023, Hubei Province, China

**Author contributions:** Yan LD, Peng XC, and Cai J designed the research; Yan LD, Yang L, Na Li, Peng XC, and Cai J performed the research; Wang M, Zhang YH, Zhou W, and Yu ZQ contributed new reagents/analytic tools; Yan LD, Peng XC, and Cai J analyzed the data; Yan LD and Cai J wrote the paper.

**Supported by** the Natural Science Foundation of Hubei Province, No. 2017CFB786; the Hubei Province Health and Family Planning Scientific Research Project, No. WJ2016Y10; the Jingzhou Science and Technology Bureau Project, No. 2017-93; and the College Students Innovative Entrepreneurial Training Program in Yangtze University, No. 2019376.

**Corresponding author: Jun Cai, MD, PhD, Chief Doctor,** Department of Oncology, The First Affiliated Hospital of Yangtze University, No. 1 Nanhuan Road, Jingzhou 434023, Hubei Province, China. 529369023@qq.com

**Received:** February 28, 2022

**Revised:** May 19, 2022

**Accepted:** June 17, 2022

**Published online:**

**Abstract**

BACKGROUND

Non-small-cell lung cancer (NSCLC) has the highest morbidity and mortality rates among all malignant tumor types. Although therapies targeting the mutated genes such as *KRAS* have been used in the clinic for many years, the prognosis remains poor. Therefore, it is necessary to further study the aberrant expression or mutation of non-target genes affecting the survival and prognosis.

AIM

To explore the impact of simultaneous abnormalities of multiple genes on the prognosis and survival of patients.

METHODS

We used R packages to analyze gene expression data and clinical data downloaded from The Cancer Genome Atlas (TCGA) database. We also collected samples from 85 NSCLC patients from the First People’s Hospital of Jingzhou City and retrospectively followed the patients. Multivariate Cox regression analysis and survival analysis were performed.

RESULTS

Analysis of gene expression data from TCGA revealed that the overexpression of the following single genes affected overall survival: *TP53* (*P* = 0.79), *PTEN* (*P* = 0.94), *RB1* (*P* = 0.49), *CTNNB1* (*P* = 0.24), *STK11* (*P* = 0.32), and *PIK3CA* (*P* = 0.013). However, the probability of multiple genes(*TP53*, *PTEN*, *RB1*, and *STK11*) affecting survival was 0.025. Retrospective analysis of clinical data revealed that sex (hazard ratio [HR] = 1.29 [95%CI: 0.64-2.62]), age (HR = 1.05 [95%CI: 1.02-1.07]), smoking status (HR = 2.26 [95%CI: 1.16-4.39]), tumor histology (HR = 0.58 [95%CI: 0.30-1.11]), cancer stage (HR = 16.63 [95%CI: 4.8-57.63]), epidermal growth factor receptor (*EGFR*) mutation (HR = 1.82 [95%CI: 1.05-3.16]), abundance (HR = 4.95 [95%CI: 0.78-31.36]), and treatment with tyrosine kinase inhibitors (TKIs) (HR = 0.58 [95%CI: 0.43-0.78]) affected patient survival. Co-occurring mutations of *TP53*, *PTEN*, *RB1*, and *STK11* did not significantly affect the overall survival of patients receiving chemotherapy (*P* = 0.96) but significantly affected the overall survival of patients receiving TKIs (*P* = 0.045).

CONCLUSION

Co-occurring mutation or overexpression of different genes has different effects on the overall survival and prognosis of NSCLC patients. Combined with TKI treatment, the co-occurring mutation of some genes may have a synergistic effect on the survival and prognosis of NSCLC patients.

**Key Words:** Non-small-cell lung cancer; Gene mutation; Tyrosine kinase inhibitor; Overexpression; Next-generation sequencing; Epidermal growth factor receptor; *KRAS*

Yan LD, Yang L, Li N, Wang M, Zhang YH, Zhou W, Yu ZQ, Peng XC, Cai J. Prognostic role of the abnormal multiple genes in non-small-cell lung cancer. *World J Clin Cases* 2022; In press

**Core Tip:** Non-small-cell lung cancer (NSCLC) has the highest morbidity and mortality rates among all malignant tumors. To explore the impact of simultaneous abnormalities of multiple genes on the prognosis and survival of patients. We used R packages to analyze gene expression data and clinical data downloaded from The Cancer Genome Atlas database. We also collected samples from 85 NSCLC patients from the First People's Hospital of Jingzhou City and retrospectively followed the patients for multivariate Cox regression analysis and survival analysis. Co-occurring mutation or overexpression of different genes has different effects on the overall survival and prognosis of patients. Combined with TKI treatment, the co-occurring mutation of some genes may have a synergistic effect on the survival and prognosis of NSCLC patients.

**INTRODUCTION**

The prognosis of lung cancer is poor, and the associated mortality rate is among the highest due to the tumor’s highly invasive and metastatic nature[1]. Non-small-cell lung cancer (NSCLC) accounts for 85% of lung malignancy cases[2]. Despite advances in gene-targeted therapy and immunotherapy, the long-term survival benefits of NSCLC patients are still limited[3]. Cancer patients receiving molecularly targeted therapies have clinically different survival prognoses mainly because currently used targeted therapies primarily target single-gene mutations, while tumor tissues are highly heterogeneous. Moreover, the complex tumor microenvironment plays a crucial role in the survival, ability to evade immune surveillance, and drug resistance of cancer cells[4].

Single-gene-targeted therapy has provided a survival benefit to patients over conventional chemotherapy. For example, patients with advanced epidermal growth factor receptor (*EGFR*) mutation-positive lung cancer can be treated with tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib, and those with anaplastic lymphoma kinase-positive lung cancer can be treated with crizotinib[5-7]. Third-generation TKIs including osimertinib further improve the survival of patients with *EGFR* mutation-positive lung cancer that is also characterized by T790M mutation, in which cases first-generation TKIs are not effective[8]. However, not all patients with *EGFR* mutation-positive lung cancer respond well to TKIs, and some even develop drug resistance, which will lead to disease progression[9].

Next-generation sequencing analyses have revealed significant differences in gene mutation sites among patients, with the differences also being apparent between early and late stages of cancer and in the mutation frequency of each site[10]. The differences in gene mutations may also be responsible for differences in the risk of drug resistance and differences in individual treatment responses.

The co-occurrence of *TP53* and *EGFR* mutations is often associated with a worse prognosis and accelerated proliferation and invasion of cancer cells[11,12]. In this study, we collected clinical data from The Cancer Genome Atlas (TCGA) and analyzed the impact of common mutations in NSCLC patients on targeted therapy and survival prognosis.

**MATERIALS AND METHODS**

***Data collection and analysis***

First, we downloaded the clinical and original gene expression data (counts) of lung adenocarcinoma (LUAD) patients from the TCGA public database. Next, we screened 21 target genes detected by second-generation sequencing during clinical treatment and observed the effect of multiple gene expression on the survival and prognosis of patients using the pheatmap package of R software to plot a heat map for visual analysis.

Then, we used the patient mutation information provided in the database and divided all patient samples into *EGFR* and *KRAS* mutation groups to study the gene expression differences and explore the correlation between mutations at other loci and these two most common mutations.

Finally, we analyzed the overall survival (OS) of patients whose samples showed different gene expression profiles. The significance of single-gene analysis was improved by considering an expression Z score of more than 1 as high expression and an expression Z score less than -1 as low expression. Then, considering 0 as the critical value, we analyzed the co-expression of multiple genes.

***Collection of clinical data from patients***

We collected the next-generation sequencing results of more than 300 NSCLC patients from the First People’s Hospital of Jingzhou City from 2017 to 2020. After follow-up, clear OS and detailed data of 85 patients were obtained. If some patients were examined many times during the treatment, we took the first detection results as the basis for analysis.

We collected the medical history and general clinical data of the subjects through the hospital information system and telephone return visit in the hospital's oncology department. We collected the patient’s sex, age, smoking history, pathological type, cancer stage, next-generation sequencing results, treatment with TKIs, OS, and other results and divided the patient population based on the gene mutation status for multivariate Cox regression analysis. Finally, the patients were divided into two groups based on whether they received targeted TKI therapy or chemotherapy to explore the effect of co-occurrence of gene mutations on the OS of patients. All clinical data were collected after being submitted to the ethics committee of Jingzhou First People’s Hospital for approval. All patients provided informed consent before the next-generation sequencing analysis.

***Statistical analysis***

All patients were followed until December 31, 2020. We screened patients with complete basic information and definite OS data. The results of all patients were obtained using the same high-throughput sequencing equipment. All statistical analyses were performed using several R packages such as edgeR, DESeq, TCGAbiolinks, and ggplot2. We used the Kaplan-Meier method to analyze the differences in OS and compared the effects of gene mutations using the log-rank test. We also investigated the influence of various factors on the total survival of patients using multivariate Cox regression analysis. The Fisher exact test was used for comparing different groups. All *P*-values are based on a two-tail hypothesis with statistical significance defined as *P <* 0.05.

**RESULTS**

***Differential gene expression***

The volcano map (Figure 1) of gene expression data of 533 cancer tissues and 53 normal tissues from TCGA reveals a large number of upregulated (red) and downregulated (green) genes[13]. Differences in gene expression were also seen among different subtypes of cancer tissues. In this study, 21 genes detected by next-generation sequencing were selected to explore the effect of gene mutation and overexpression on OS. A two-dimensional heat map of various parameters was plotted to intuitively observe patients' basic indicators and gene expression (Figure 2, which shows apparent differences in the expression of different genes, but it is necessary to clarify which indicators impact the OS of patients.

Clinical data regarding the *EGFR* and *KRAS* mutation status were also analyzed and compared with data on mutations of other genes[14,15]. The National Comprehensive Cancer Network guidelines have pointed out that *KRAS* mutation can reduce sensitivity toward *EGFR* inhibitors. Clinically, the probability of simultaneous occurrence of *KRAS* mutation and *EGFR* mutation is very low, and a mutually exclusive relationship between them is also reported[16]. After grouping the samples based on the *EGFR* and *KRAS* mutation status with more than 20 samples in each group, the prepared bubble chart and box chart (Figure 3) show that *RET*, *KIT*, and *TERT* exhibited significantly different expression levels between the two groups. These three genes were upregulated in patients with *KRAS* mutation, while *EGFR* and *BRAF* were downregulated (Figure 3).

In the analysis of the survival of patients with single-gene mutations, to amplify the single-gene effect, we considered genes with a Z score greater than 1 to be highly expressed and those with a Z score less than -1 to have a low expression level. After calculating the *P* value, it was found that except for *PIK3CA* (*P <* 0.05), there was no statistical significance in the high expression of other single genes: *TP53* (*P* = 0.79), *PTEN* (*P* = 0.94), *RB1* (0.49), *CTNNB1* (*P* = 0.24), and *STK11* (*P* = 0.32) (Figure 4). We speculated that significant *PIK3CA* overexpression indicates a poor prognosis and OS[17-19]. Given that the expression of other single genes did not seem to affect prognosis significantly, we suspected that the simultaneous overexpression of multiple genes, especially the four tumor suppressor genes (*TP53*, *PTEN*, *RB1*, and *STK11*), would have some clinical implication. Therefore, we used the Z score of 0 as the critical value and divided the four genes into two groups in which all had a high expression or a low expression level at the same time (Figure 5). A *P* value of 0.025 showed that when *TP53*, *PTEN*, *RB1*, and *STK11* were highly expressed simultaneously, the OS was significantly different from that when these genes showed a low expression level. Moreover, the high expression group had a significantly shorter OS.

***Differences in co-occurrence of gene mutations between patients receiving chemotherapy and TKI therapy***

We visualized data regarding gene mutations and basic clinical information collected from patients by plotting a heat map (Figure 6). First, we divided the patients based on whether they received chemotherapy or TKI therapy and then carried out Fisher's exact test (Table 1). We found that sex (*P* = 0.0021), smoking history (*P* = 0.0302), and OS (*P* = 0.0022) differed significantly based on the treatment. To understand the impact of various factors on patients, we separately analyzed the impact of basic indicators and gene mutations by multivariate Cox regression (Figure 7), which demonstrated that sex (hazard ratio [HR] = 1.29 [95%CI: 0.64-2.62]; *P* = 0.475), age (HR = 1.05 [95%CI: 1.02-1.07]; *P <* 0.001), smoking history (HR = 2.26 [95%CI: 1.16-4.39]; *P* = 0.017), tumor histology (HR = 0.58 [95%CI: 0.30-1.11]; *P* = 0.098), cancer stage (HR = 16.63 [95%CI: 4.8-57.63]; *P <* 0.001), EGFR mutation (HR = 1.82 [95%CI: 1.05-3.16]; *P* = 0.034), abundance (HR = 4.95 [95%CI: 0.78-31.36]; *P* = 0.09), and TKI treatment (HR = 0.58 [95%CI: 0.43-0.78]; *P <* 0.001) affected patient survival.

Cox regression analysis (Figure 8) revealed a significant effect of all gene mutations except for *BRAF* (*P* = 0.02), which indicates that the OS of patients is under the combined influence of multiple-locus genes. The HR values of some gene mutations were positive, such as *MAP2K1* (HR = 0.0014), *CTNNB1* (HR = 0.1629), and *RET* (HR = 0.1089), indicating that mutations of these genes may benefit the patients, but further confirmation using more samples is necessary. We selected *TP53*, *PTEN*, *Rb1*, and *STK11*, whose mutation frequency is high in NSCLC patients, to study if the co-occurrence of mutations of these genes has a similar superposition effect[20-22]. Patients with mutations in these tumor suppressor genes have a worse survival prognosis[23,24]. These co-occurring mutations can allow cancer cells to escape immune surveillance, proliferate aberrantly to malignancy, and develop resistance to targeted therapy. After identifying the effect of *TP53* (HR = 1.2602), *PTEN* (HR = 1.4428), *Rb1* (HR = 2.2605), and *STK11* (HR = 3.5352), we sought to determine whether either of them could be used individually as an indicator of survival and prognosis of patients. However, the effect of age (*P <* 0.001) was significant even if its HR value was only 1.05 (Figure 7).

The patients were divided into two groups based on whether they received chemotherapy (*n* = 41) or TKI treatment (*n* = 44). According to the number of mutations in the four tumor suppressor genes (*TP53*, *PTEN*, *Rb1*, and *STK11*), we classified those with more than one mutation into the greater than (GT) 1 group (Figure 9). The number of mutations of these tumor suppressor genes in the chemotherapy group did not bear significance between the GT1 and non-GT1 groups (*P* = 0.96). Still, it was significant in the TKI treatment group (*P* = 0.045). Co-occurrence of mutations in these genes worsened the prognosis similarly in both groups. We found that some patients discontinued targeted therapy not because of disease progression but because of economic reasons; this could have affected the results. The complexity of the tumor genome determines that cancer treatment cannot target a single gene. Co-mutation is likely to completely change the biological characteristics of the original tumor through synergy, endow the tumor with new biological characteristics, and make the tumor tolerant to targeted therapy. This co-mutation may occur gradually in the process of targeted therapy.

**DISCUSSION**

In this study, we focused on the effect of the co-occurrence of gene mutations using TCGA database and clinical patient data. Our analyses revealed significant differences in the gene expression profiles between adenocarcinoma and normal tissues in NSCLC. The upregulated and downregulated genes also differed in different patients and between LUAD patients with *EGFR* and *KRAS* mutations. Most tumor-derived *TP53* mutations occur in the region encoding the DNA binding domain of p53. The *TP53* mutation significantly impacts the progression of various types of cancer[25,26]. While the overexpression of some genes was significantly associated with good OS and prognosis, such as *PIK3CA*, the single expression of most genes did not have a significant effect. The simultaneous overexpression of multiple tumor suppressor genes (*TP53*, *PTEN*, *RB1*, and *STK11*) was associated with a poor OS. Cox multivariate regression analysis revealed that for NSCLC patients, the most critical factor affecting OS was not the type of treatment or gene mutation but the disease stage, which underscores the importance of early diagnosis of solid tumors. The effects of recognized risk factors such as smoking history were also confirmed in the analysis. Finally, after grouping based on treatment, we found that in patients receiving traditional chemotherapy, mutations of *TP53*, *PTEN*, *RB1*, and *STK11* had no significant influence on the OS; however, these mutations had a significant effect in patients receiving TKIs. Simultaneous mutations in multiple tumor suppressor genes resulted in a risk superposition effect[24].

These genes have been studied in the context of non-target therapy. While the frequency of mutations in these genes is high in NSCLC patients, the problem of tumor heterogeneity and the possibility of personalized medicine need to be further explored. The influence of these gene mutations on the OS and prognosis of patients receiving immunotherapy has also received attention[27-29]. In the future, the development of new molecular targeted drugs will help deal with the heterogeneity of different mutant subtypes.

**CONCLUSION**

In conclusion, this study summarizes the impact of the co-occurrence of mutations or overexpression of multiple genes on the OS and prognosis of NSCLC patients. The results indicate that the co-occurrence of mutations results in a risk superposition effect, and such genes must be studied further when predicting patients' disease progression.

**ARTICLE HIGHLIGHTS**

***Research background***

Among all malignant tumor types, non-small cell lung cancer (NSCLC) has the highest incidence rate and mortality.

***Research motivation***

To investigate the effect of simultaneous polygenic abnormalities on the prognosis and survival of NSCLC patients.

***Research objectives***

To study the effect of polygene mutation and abnormal expression on the prognosis and survival of patients with non-small cell lung cancer.

***Research methods***

We used R packages to analyze gene expression data and clinical data downloaded from The Cancer Genome Atlas (TCGA) database. We also collected samples from 85 NSCLC patients from the First People’s Hospital of Jingzhou City and retrospectively followed the patients. Multivariate Cox regression analysis and survival analysis were performed.

***Research results***

The probability of multiple genes(*TP53*, *PTEN*, *RB1*, and *STK11*) affecting survival was 0.025. Retrospective analysis of clinical data revealed that sex (hazard ratio [HR] = 1.29), age (HR = 1.05), smoking status (HR = 2.26), tumor histology (HR = 0.58), cancer stage (HR = 16.63), epidermal growth factor receptor (*EGFR*) mutation (HR = 1.82), abundance (HR = 4.95), and treatment with tyrosine kinase inhibitors (TKIs) (HR = 0.58) affected patient survival. Co-occurring mutation of *TP53*, *PTEN*, *RB1*, and *STK11* did not significantly affect the overall survival of patients receiving chemotherapy (*P* = 0.96) but significantly affected the overall survival of patients receiving TKIs (*P* = 0.045).

***Research conclusions***

Co-mutation or overexpression of different genes has different effects on the overall survival and prognosis of NSCLC patients. Combined with TKI treatment, the co-mutations of some genes may have a synergistic effect on the survival and prognosis of NSCLC patients.

***Research perspectives***

In the future, the development of new molecular targeted drugs will help deal with the heterogeneity of different mutant subtypes.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]

2 **Arbour KC**, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. *JAMA* 2019; **322**: 764-774 [PMID: 31454018 DOI: 10.1001/jama.2019.11058]

3 **Hastings K**, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. *Ann Oncol* 2019; **30**: 1311-1320 [PMID: 31086949 DOI: 10.1093/annonc/mdz141]

4 **Kim J**, DeBerardinis RJ. Mechanisms and Implications of Metabolic Heterogeneity in Cancer. *Cell Metab* 2019; **30**: 434-446 [PMID: 31484055 DOI: 10.1016/j.cmet.2019.08.013]

5 **Zhang L**, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib *vs* placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. *Lancet Oncol* 2012; **13**: 466-475 [PMID: 22512843 DOI: 10.1016/S1470-2045(12)70117-1]

6 **Herbst RS**, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib *vs* erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. *Lancet* 2011; **377**: 1846-1854 [PMID: 21621716 DOI: 10.1016/S0140-6736(11)60545-X]

7 **Shaw AT**, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced *ALK*-Positive Lung Cancer. *N Engl J Med* 2020; **383**: 2018-2029 [PMID: 33207094 DOI: 10.1056/NEJMoa2027187]

8 **Wu YL**, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected *EGFR*-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med* 2020; **383**: 1711-1723 [PMID: 32955177 DOI: 10.1056/NEJMoa2027071]

9 **Ramalingam SS**, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, *EGFR*-Mutated Advanced NSCLC. *N Engl J Med* 2020; **382**: 41-50 [PMID: 31751012 DOI: 10.1056/NEJMoa1913662]

10 **Cancer Genome Atlas Research Network.**. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014; **511**: 543-550 [PMID: 25079552 DOI: 10.1038/nature13385]

11 **VanderLaan PA**, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. *Lung Cancer* 2017; **106**: 17-21 [PMID: 28285689 DOI: 10.1016/j.lungcan.2017.01.011]

12 **Skoulidis F**, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. *Nat Rev Cancer* 2019; **19**: 495-509 [PMID: 31406302 DOI: 10.1038/s41568-019-0179-8]

13 **Zhang B**, Zhang L, Yue D, Li C, Zhang H, Ye J, Gao L, Zhao X, Chen C, Huo Y, Pang C, Li Y, Chen Y, Chuai S, Zhang Z, Giaccone G, Wang C. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. *Transl Lung Cancer Res* 2020; **9**: 1187-1201 [PMID: 32953497 DOI: 10.21037/tlcr-19-664]

14 **Roberts PJ**, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? *J Clin Oncol* 2010; **28**: 4769-4777 [PMID: 20921461 DOI: 10.1200/JCO.2009.27.4365]

15 **Kim D**, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. *Cell* 2020; **183**: 850-859 [PMID: 33065029 DOI: 10.1016/j.cell.2020.09.044]

16 **Amodio V**, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. *Cancer Discov* 2020; **10**: 1129-1139 [PMID: 32430388 DOI: 10.1158/2159-8290.CD-20-0187]

17 **Aldea M**, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. *J Thorac Oncol* 2020; **15**: 383-391 [PMID: 31843682 DOI: 10.1016/j.jtho.2019.11.024]

18 **Fang W**, Huang Y, Gu W, Gan J, Wang W, Zhang S, Wang K, Zhan J, Yang Y, Huang Y, Zhao H, Zhang L. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. *Transl Lung Cancer Res* 2020; **9**: 1258-1267 [PMID: 32953503 DOI: 10.21037/tlcr-20-141]

19 **Jamme P**, Fernandes M, Copin MC, Descarpentries C, Escande F, Morabito A, Grégoire V, Jamme M, Baldacci S, Tulasne D, Kherrouche Z, Cortot AB. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. *J Thorac Oncol* 2020; **15**: 741-751 [PMID: 32169477 DOI: 10.1016/j.jtho.2020.01.027]

20 **Lopez-Chavez A**, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. *J Clin Oncol* 2015; **33**: 1000-1007 [PMID: 25667274 DOI: 10.1200/JCO.2014.58.2007]

21 **Mazieres J**, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019; **30**: 1321-1328 [PMID: 31125062 DOI: 10.1093/annonc/mdz167]

22 **Passaro A**, Attili I, Rappa A, Vacirca D, Ranghiero A, Fumagalli C, Guarize J, Spaggiari L, de Marinis F, Barberis M, Guerini-Rocco E. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. *Cancers (Basel)* 2021; **13** [PMID: 33946519 DOI: 10.3390/cancers13092172]

23 **Wang F**, Zhao N, Gao G, Deng HB, Wang ZH, Deng LL, Yang Y, Lu C. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. *J Cancer Res Clin Oncol* 2020; **146**: 2851-2859 [PMID: 32743759 DOI: 10.1007/s00432-020-03340-5]

24 **Chevallier M**, Tsantoulis P, Addeo A, Friedlaender A. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. *Cancer Genomics Proteomics* 2020; **17**: 597-603 [PMID: 32859638 DOI: 10.21873/cgp.20216]

25 **El-Arabey AA**, Abdalla M, Abd-Allah AR. SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors. *Int Immunopharmacol* 2020; **86**: 106758 [PMID: 32663767 DOI: 10.1016/j.intimp.2020.106758]

26 **El-Arabey AA**, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. *Cell Signal* 2022; **89**: 110147 [PMID: 34772589 DOI: 10.1016/j.cellsig.2021.110147]

27 **Alos L**, Fuster C, Castillo P, Jares P, Garcia-Herrera A, Marginet M, Agreda F, Arance A, Gonzalvo E, Garcia M, Puig S, Teixido C. *TP53* mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. *Ann Transl Med* 2020; **8**: 1218 [PMID: 33178750 DOI: 10.21037/atm-20-1846]

28 **Fang C**, Zhang C, Zhao WQ, Hu WW, Wu J, Ji M. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report. *BMC Med Genomics* 2019; **12**: 136 [PMID: 31619231 DOI: 10.1186/s12920-019-0592-6]

29 **Biton J**, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. *TP53, STK11*, and *EGFR* Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. *Clin Cancer Res* 2018; **24**: 5710-5723 [PMID: 29764856 DOI: 10.1158/1078-0432.CCR-18-0163]

30 **Bersani F**, Morena D, Picca F, Morotti A, Tabbò F, Bironzo P, Righi L, Taulli R. Future perspectives from lung cancer pre-clinical models: new treatments are coming? *Transl Lung Cancer Res* 2020; **9**: 2629-2644 [PMID: 33489823 DOI: 10.21037/tlcr-20-189]

31 **Kuang PP**, Li N, Liu Z, Sun TY, Wang SQ, Hu J, Ou W, Wang SY. Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. *Front Oncol* 2020; **10**: 595650 [PMID: 33659207 DOI: 10.3389/fonc.2020.595650]

32 **Page K**, Martinson LJ, Hastings RK, Fernandez-Garcia D, Gleason KLT, Gray MC, Rushton AJ, Goddard K, Guttery DS, Stebbing J, Coombes RC, Shaw JA. Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. *Ann Oncol* 2021; **32**: 1057-1060 [PMID: 33932505 DOI: 10.1016/j.annonc.2021.04.018]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Health Science Center of Yangtze University Institutional Review Board (Approval No. 2020-036).

**Informed consent statement:** The requirement to obtain informed consent was waived by Yangtze University Ethics Board.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 28, 2022

**First decision:** May 11, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cho SG, South Korea; Sezer HF, Turkey **A-Editor:** Anaya-Prado R, Mexico **S-Editor:** Wang LL **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**

****

**Figure 1 Volcano map of gene expression data of 533 cancer tissues and 53 normal tissues from The Cancer Genome Atlas database reveals a large number of upregulated (red) and downregulated (green) genes.** LUAD: Lung adenocarcinoma.

****

**Figure 2 Two-dimensional heat map of various parameters plotted to intuitively observe patients' basic indicators and gene expression.**

****

**Figure 3 Bubble chart and box chart show that *RET*, *KIT*, and *TERT* exhibit significantly different expression levels between the two groups.** The samples were grouped based on the epidermal growth factor receptor and *KRAS* mutation status with more than 20 samples in each group.

****

**Figure 4 Analysis of survival of patients with single-gene mutations.** To amplify the single-gene effect, we considered genes with a Z score greater than 1 to be highly expressed and those with a Z score less than -1 to have a low expression level.

****

**Figure 5 We used the Z score of 0 as the critical value and divided the four genes into two groups in which all had a high expression or a low expression level at the same time.**

****

**Figure 6 Heat map revealing data regarding gene mutations and basic clinical information collected from patients.** LUAD: Lung adenocarcinoma; WT: Wild type; Del 19: Deletion of exon 19; LUSC: Lung squamous cell carcinoma; TKI: Tyrosine kinase inhibitor; OS: Overall survival.

****

**Figure 7 Multivariate Cox regression analysis of impact of basic indicators and gene mutations.**

****

**Figure 8 Cox regression analysis revealed a significant effect of all gene mutations except for *BRAF* (*P* = 0.02).**

****

**Figure 9 According to the number of mutations in the four tumor suppressor genes (*TP53*, *PTEN*, *Rb1*, and *STK11*), we classified those with more than one mutation into the greater than 1 group.** gt1: Greater than 1; TKI: Tyrosine kinase inhibitor; OS: Overall survival.

**Table 1 Variables between patients who received chemotherapy or TKI therapy**

|  |  |  |  |
| --- | --- | --- | --- |
| **Therapy type** | **Chemotherapy** | **TKI therapy**  | ***P* value** |
| Sex |  |  |  |
| Female | 7 (8.2) | 20 (23.5) | 0.0021 |
| Male | 37 (43.5) | 21 (23.7) |  |
| Age |  |  |  |
| Less than 50 yr | 7 (8.2) | 4 (4.7) | 0.7334 |
| 50-70 yr | 27 (31.8) | 26 (30.6) |  |
| Greater than 70 yr | 10 (11.8) | 11 (12.9) |  |
| Smoking history |  |  |  |
| Ever | 27 (31.7) | 15 (17.6) | 0.0302 |
| Never | 17 (20.0) | 26 (30.6) |  |
| Tumor histology |  |  |  |
| LUAD | 35 (41.1) | 37 (43.5) | 0.2317 |
| LUSC & Others | 9 (10.6) | 4 (4.7) |  |
| Cancer stage |  |  |  |
| I and II | 2 (2.4) | 4 (4.7) | 0.4227 |
| III and IV | 42 (49.4) | 37 (43.5) |  |
| OS |  |  |  |
| < 12 mo | 28 (32.9) | 12 (14.1) | 0.0022 |
| ≥ 12 mo | 16 (18.8) | 29 (34.1) |  |

TKI: Tyrosine kinase inhibitor; LUAD: Lung adenocarcinoma; OS: Overall survival.